



US009133479B2

(12) **United States Patent**
Sharifi et al.

(10) **Patent No.:** **US 9,133,479 B2**
(45) **Date of Patent:** **Sep. 15, 2015**

(54) **EFFECTIVE VECTOR PLATFORM FOR GENE TRANSFER AND GENE THERAPY**

(75) Inventors: **Behrooz Sharifi**, Woodland Hills, CA (US); **Prediman K. Shah**, Los Angeles, CA (US)

(73) Assignee: **Cedars-Sinai Medical Center**, Los Angeles, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/375,285**

(22) PCT Filed: **Jun. 3, 2010**

(86) PCT No.: **PCT/US2010/037239**

§ 371 (c)(1),

(2), (4) Date: **Nov. 30, 2011**

(87) PCT Pub. No.: **WO2010/141706**

PCT Pub. Date: **Dec. 9, 2010**

(65) **Prior Publication Data**

US 2012/0070899 A1 Mar. 22, 2012

Related U.S. Application Data

(60) Provisional application No. 61/183,862, filed on Jun. 3, 2009.

(51) **Int. Cl.**

C12N 15/86 (2006.01)

C07K 14/005 (2006.01)

(52) **U.S. Cl.**

CPC **C12N 15/86** (2013.01); **C07K 14/005** (2013.01); **C12N 2750/14122** (2013.01); **C12N 2750/14143** (2013.01); **C12N 2830/50** (2013.01)

(58) **Field of Classification Search**

CPC C12N 15/86; C12N 7/00; C12N 2800/22; C12N 2710/16142; C12N 2710/16442; C12N 2710/16622; C12N 2750/14011; C12N 2810/50; C12N 2810/858; C12Q 1/70

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,156,303 A * 12/2000 Russell et al. 424/93.2
6,855,314 B1 * 2/2005 Chiorini et al. 424/93.2
7,906,111 B2 * 3/2011 Wilson et al. 424/93.2
2002/0192823 A1 12/2002 Bartlett
2007/0202081 A1 8/2007 Shah et al.

FOREIGN PATENT DOCUMENTS

EP 1732383 A2 12/2006
JP 2007531537 A 11/2007
WO WO2005033321 * 4/2005
WO 2005097206 A2 10/2005
WO 2010141706 A1 12/2010

OTHER PUBLICATIONS

Wu et al. J. Virol. 2006, vol. 80, No. 22, pp. 11393-11397.*
Miki et al. J. Biologi. Chemist. 1999, vol. 274, No. 41, pp. 29057-29062.*
PCT/US 2010/037239 International Search Report dated Aug. 13, 2010.
PCT/US 2010/037239 Written Opinion dated Aug. 13, 2010.
PCT/US 2010/037239 International Preliminary Report on Patentability dated Dec. 6, 2011.
Cardozo et al. The SCF Ubiquitin Ligase: Insights into a Molecular Machine. Molecular Cell Biology (2004). 5:739-751.
Grimm et al. From Virus Evolution to Vector Revolution: Use of Naturally Occurring Serotypes of Adeno-Associated Virus (AAV) as Novel Vectors for Human Gene Therapy. Current Gene Therapy (2003). 3(4):281-304.
Kanemori et al. B-TrCP Recognizes a Previously Undescribed Nonphosphorylated Destruction Motif in Cdc25A and Cdc25B Phosphatases. PNAS (2005). 102(18):6279-6284.
Orford et al. Serine Phosphorylation-regulated Ubiquitination and Degredation of B-Catenin. The Journal of Biological Chemistry (1997). 272(40): 24735-24738.
Yan et al. Ubiquitination of both Adeno-Associated Virus Type 2 and 5 Capsid Proteins Affects the Transduction Efficiency of Recombinant Vectors. Journal of Virology (2002). 76(5): 2043-2053.
Zhong et al. Next Generation of Adeno-Associated Virus 2 Vectors: Point Mutations in Tyrosines Lead to High-Efficiency Transduction at Lower Doses. PNAS (2008). 105(22): 7827-7832.

* cited by examiner

Primary Examiner — Bao Li

(74) *Attorney, Agent, or Firm* — Seth D. Levy; Nixon Peabody LLP

(57) **ABSTRACT**

The invention relates to the discovery that mutations of serine residues of an AAV capsid results in significantly greater transfection efficiency than the wild type AAV2 virus. In one embodiment, the present invention provides a method of improving efficiency of gene transfer and/or gene therapy to a cell by inhibiting phosphorylation of one or more serine residues of a virus capsid protein, where the inhibition of the phosphorylation of one or more serine residues results in a decrease of ubiquitination of the virus capsid protein in the cell. In another embodiment, one of the one or more serine residues is Serine 264. In another embodiment, the Serine 264 residue is mutated to Alanine (S 264 A).

11 Claims, 7 Drawing Sheets


Figure 1.


Figure 2.

Figure 3 (a)




Figure 3 (b)




Figure 3 (c)




Figure 4 (a)




Figure 4 (b)




Figure 4 (c)




Figure 5.

```
1 maadgylpdw ledtlsegir qwwklkpgrp ppkpaerhkd dsrglvlpgy kylgpfngld
61 kgepvneada aalehdkayd rqlsdgdnpy lkynhadaef qerlkedtsf ggnlgravfq
121 akkrvleplg lveepvktap gkkrpvehsp vepdsssgtg kagqqparkr lnfgqtgdad
181 svdpdpqlgq ppaapsglgt ntmatgsgap madnnegadg vgnssgnwhc dstwmgdrvi
241 ttstrtwalp tynnhlykqi ssqsgasndn hyfgystpwg yfdfnrfhch fsprdwqrli
301 nnnwgfrpkr lnfklfniqv kevtqndgtt tiannltstv qvftdseyql pyvlgsahqg
361 clppfpadvf mvpqygyltl nngsqavgrs sfycleyfps qmlrtggnft fsytfedvpf
421 hssyahsqs1 drlmnplidq ylyylsrtnt psqtttqsrl qfsqagasdi rdqsrnwlpq
481 pcyrqqrsvk tsadnnnsey swtgatkyhl ngrdslvnpg pamashkdde ekffpqsgvl
541 ifgkqgsekt nvdiekvmi deeeirttnp vateqygsvs tnlqrgnrqa atadvntqgv
601 lpgmvwqdrd vylqgpiwak iphtdghfhp splmggfglk hpppqilikh tpvpanpstt
661 fsaakfasfi tqystgqsv eiewelqken skrwnpeiqy tsynksvvnv dftvdtngvy
721 seprpigtry ltrnl (SEQ. ID. NO.: 1)
```

Figure 6.

```
1 maadgylpdw ledtlsegir qwwklkpgrp ppkpaerhkd dsrglvlpgy kylgpfngld
61 kgepvneada aalehdkayd rqlsdgdnpy lkynhadaef qerlkedtsf ggnlgravfq
121 akkrvleplg lveepvktap gkkrpvehsp vepdsssgtg kagqqparkr lnfgqtgdad
181 svdpdpqlgq ppaapsglgt ntmatgsgap madnnegadg vgnssgnwhc dstwmgdrvi
241 ttstrtwalp tynnhlykqi ssqagasndn hyfgystpwg yfdfnrfhch fsprdwqrli
301 nnnwgfrpkr lnfklfniqv kevtqndgtt tiannltstv qvftdseyql pyvlgsahqg
361 clppfpadvf mvpqygyltl nngsqavgrs sfycleyfps qmlrtggnft fsytfedvpf
421 hssyahsqs1 drlmnplidq ylyylsrtnt psqtttqsrl qfsqagasdi rdqsrnwlpq
481 pcyrqqrsvk tsadnnnsey swtgatkyhl ngrdslvnpg pamashkdde ekffpqsgvl
541 ifgkqgsekt nvdiekvmi deeeirttnp vateqygsvs tnlqrgnrqa atadvntqgv
601 lpgmvwqdrd vylqgpiwak iphtdghfhp splmggfglk hpppqilikh tpvpanpstt
661 fsaakfasfi tqystgqsv eiewelqken skrwnpeiqy tsynksvvnv dftvdtngvy
721 seprpigtry ltrnl (SEQ. ID. NO.: 2)
```

Figure 7.

```
1 maadgylpdw ledtlsegir qwwklkpgrp ppkpaerhkd dsrglvlpgy kylgpfngld
61 kgepvneada aalehdkayd rqlsdgdnpy lkynhadaef qerlkedtsf ggnlgravfq
121 akkrvleplg lveepvktap gkkrpvehsp vepdsssgtg kagqqparkr lnfgqtgdad
181 svdpdpqlgq ppaapsglgt ntmatgsgap madnnegadg vgnssgnwhc dstwmgdrvi
241 ttstrtwalp tynnhlykqi ssqagaandn hyfgystpwg yfdfnrfhch fsprdwqrli
301 nnnwgfrpkr lnfklfniqv kevtqndgtt tiannltstv qvftdseyql pyvlgsahqg
361 clppfpadvf mvpqygyltl nngsqavgrs sfycleyfps qmlrtggnft fsytfedvpf
421 hssyahsqs1 drlmnplidq ylyylsrtnt psqtttqsrl qfsqagasdi rdqsrnwlpq
481 pcyrqqrsvk tsadnnnsey swtgatkyhl ngrdslvnpg pamashkdde ekffpqsgvl
541 ifgkqgsekt nvdiekvmi deeeirttnp vateqygsvs tnlqrgnrqa atadvntqgv
601 lpgmvwqdrd vylqgpiwak iphtdghfhp splmggfglk hpppqilikh tpvpanpstt
661 fsaakfasfi tqystgqsv eiewelqken skrwnpeiqy tsynksvvnv dftvdtngvy
721 seprpigtry ltrnl (SEQ. ID. NO.: 3)
```


1

EFFECTIVE VECTOR PLATFORM FOR GENE TRANSFER AND GENE THERAPY

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a National Phase of International Application No. PCT/US2010/037239, filed Jun. 3, 2010, which designated the U.S. and that International Application was published under PCT Article 21(2) in English. This application also includes a claim of priority under 35 U.S.C. §119(e) to U.S. provisional patent application No. 61/183,862 filed Jun. 3, 2009.

FIELD OF THE INVENTION

The invention relates generally to the field of virology and genetics, specifically to gene transfer.

BACKGROUND

All publications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The following description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.

Gene transfer vectors based upon the nonpathogenic parvovirus, adeno-associated virus (AAV), have recently emerged as promising tools for therapeutic gene transfer. Due to their relatively low immunogenicity and high transduction efficiency, AAV serotype 2 (AAV2) vectors have advanced to the forefront of human gene therapy. The recombinant AAV virus have been shown to transduce a wide array of cells and tissues in vitro and in vivo¹⁻⁵. The AAV vectors are currently in use in Phase I/II clinical trials for gene therapy of cystic fibrosis, α -1 anti-trypsin deficiency, muscular dystrophy, factor IX-deficiency, and Parkinson's disease^{6, 7, 8}. However, some studies suggest that the transduction efficiency of AAV2 vectors in certain tissues types fall short of requirement for adequate level of gene expression^{9, 10}.

The ubiquitin-proteasome pathway is reported to play an important role in the intracellular trafficking of AAV2 virus^{11, 12}. It is reported that AAV2 capsids are phosphorylated at tyrosine residues by the epidermal growth factor receptor (EGFR) tyrosine kinase, but not at serine/threonine residues by casein kinase II (CKII) under cell-free conditions in vitro, and that AAV2 tyrosine-phosphorylation negatively affects viral intracellular trafficking and transgene expression in intact cells in vivo¹³. Recently, it has been reported that mutations of surface-exposed tyrosine residues on AAV2 capsids prevents ubiquitination of AAV2 thereby blocking proteasome-mediated degradation leading to generation of high-titer virus that is required for gene therapy¹⁴.

Thus, identification of amino acid motif within a protein sequence such as capsid protein of viruses would be extremely helpful in understanding viral trafficking and its stability in vitro and in vivo systems.

SUMMARY OF THE INVENTION

Various embodiments include a vector, comprising an isolated adeno-associated virus (AAV) capsid comprising one or more mutations that resist ubiquitination. In another embodi-

2

ment, the one or more mutations that resist ubiquitination comprise an amino acid substitution of a serine residue. In another embodiment, the one or more mutations that resist ubiquitination comprise a Serine 264 Alanine motif. In another embodiment, the one or more mutations that resist ubiquitination comprise an amino acid insertion following amino acid position 264 in an AAV capsid. In another embodiment, the isolated AAV capsid comprises SEQ. ID. NO.: 2. In another embodiment, the isolated AAV capsid comprises SEQ. ID. NO.: 3. In another embodiment, the isolated AAV capsid comprises AAV2. In another embodiment, the isolated AAV capsid comprises AAV8. In another embodiment, the isolated AAV capsid comprises AAV1, AAV3, AAV4, AAV5, AAV6 or AAV7.

Other embodiments include a method of increasing transfection efficiency in an adeno-associated virus (AAV) capsid, comprising providing an AAV capsid, and mutating one or more residues on the AAV capsid to resist ubiquitination. In another embodiment, mutating one or more residues on the AAV capsid to resist ubiquitination comprises inhibition of phosphorylation of one or more AAV capsid serine residues. In another embodiment, mutating one or more residues on the AAV capsid to resist ubiquitination comprises mutating Serine 264 into Alanine. In another embodiment, mutating one or more residues on the AAV capsid to resist ubiquitination comprises inserting an amino acid residue before Serine 264. In another embodiment, the AAV capsid comprises SEQ. ID. NO.: 1, SEQ. ID. NO.: 2 and/or SEQ. ID. NO.: 3. In another embodiment, the AAV capsid comprises AAV2. In another embodiment, the AAV capsid comprises AAV8. In another embodiment, the AAV capsid comprises AAV1, AAV3, AAV4, AAV5, AAV6 or AAV7.

Other embodiments include a method of transfecting a cell, comprising providing an isolated adeno-associated virus (AAV) capsid comprising one or more mutations that resist ubiquitination, and transfecting the cell with the AAV capsid. In another embodiment, the cell is a HeLa and/or HepG2 cell. In another embodiment, the cell is transfected directly. In another embodiment, the one or more mutations that resist ubiquitination comprise an amino acid substitution of a serine residue. In another embodiment, the one or more mutations that resist ubiquitination comprise a Serine 264 Alanine motif. In another embodiment, the one or more mutations that resist ubiquitination comprise an amino acid insertion following amino acid position 264 in an AAV capsid. In another embodiment, the isolated AAV capsid comprises SEQ. ID. NO.: 2. In another embodiment, the isolated AAV capsid comprises SEQ. ID. NO.: 3. In another embodiment, the isolated AAV capsid comprises AAV2. In another embodiment, the isolated AAV capsid comprises AAV8. In another embodiment, the isolated AAV capsid comprises AAV1, AAV3, AAV4, AAV5, AAV6 or AAV7.

Other features and advantages of the invention will become apparent from the following detailed description, taken in conjunction with the accompanying drawings, which illustrate, by way of example, various embodiments of the invention.

BRIEF DESCRIPTION OF THE FIGURES

Exemplary embodiments are illustrated in referenced figures. It is intended that the embodiments and figures disclosed herein are to be considered illustrative rather than restrictive.

FIG. 1 depicts, in accordance with an embodiment herein, charts of transduction efficiency in HeLa cells. Cells were plated in wells of a 24 well plate with a density of 1.0E5 cells per well. After 16 hours, the cells were transduced with

3

different types of virus with a density of 1.0E9, 0.5E9 and 0.25E9 genomic particles per well. After 48 hours after the cells were transduced, the cells were collected and GFP positive cells were detected with FACS.

FIG. 2 depicts, in accordance with an embodiment herein, charts of transduction efficiency in HepG2 cells. Cells were plated in wells of a 24 well plate with a density of 1.0E5 cells per well. After 16 hours, the cells were transduced with different types of virus with a density of 1.0E9, 0.5E9 and 0.25E9 genomic particles per well, after transduced 48 hours, cell were collected and GFP positive cells were detected with FACS.

FIG. 3 (a)-(c) depicts, in accordance with an embodiment herein, HepG2 cells, with (a) wild type, (b) S 264 A Clone 1, and (c) S 264 A Clone 2 as viewed as fluorescence microscopy images.

FIG. 4 (a)-(c) depicts, in accordance with an embodiment herein, HeLa cells, with (a) wild type, (b) S 264 A Clone 1, and S 264 A Clone 2 as viewed as fluorescence microscopy images.

FIG. 5 depicts, in accordance with an embodiment herein, an example of an AAV amino acid sequence, including the 264 SGAS 267 motif, at amino acid positions 264-267, which has been underlined. The sequence is also described herein as SEQ. ID. NO.: 1.

FIG. 6 depicts, in accordance with an embodiment herein, an example of an AAV amino acid sequence where the Serine residue at position 264 has been substituted with an Alanine residue. The 264 AGAS 267 motif has been underlined. The sequence is also described herein as SEQ. ID. NO.: 2.

FIG. 7 depicts, in accordance with an embodiment herein, an example of an AAV amino acid sequence where the Serine residues at both positions 264 and at 267 has been substituted with Alanine residues. The 264 AGAA 267 motif has been underlined. The sequence is also described herein as SEQ. ID. NO.: 3.

DESCRIPTION OF THE INVENTION

All references cited herein are incorporated by reference in their entirety as though fully set forth. Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton et al., *Dictionary of Microbiology and Molecular Biology* 3rd ed., J. Wiley & Sons (New York, N.Y. 2001); March, *Advanced Organic Chemistry Reactions, Mechanisms and Structure* 5th ed., J. Wiley & Sons (New York, N.Y. 2001); and Sambrook and Russel, *Molecular Cloning: A Laboratory Manual* 3rd ed., Cold Spring Harbor Laboratory Press (Cold Spring Harbor, N.Y. 2001), provide one skilled in the art with a general guide to many of the terms used in the present application.

One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is in no way limited to the methods and materials described.

As used herein, "AAV" means adeno-associated virus.

As used herein, "264 SGAS 267" describes a motif of AAV where amino acid positions 264-267 are made up of S, G, A and S amino acids, respectively. The 264 SGAS 267 motif is described herein as SEQ. ID. NO.: 4, as well as SEQ. ID. NO.: 1.

As disclosed herein, the inventors mutated the amino acid Serine 264 into Alanine. The HeLa and HepG2 cells, two cell types that are widely used for the transfection of AAV2 virus was transfected with the mutated virus expressing green flo-

4

rescent protein (GFP) as a reporter gene. Transfection with the wild type AAV2 virus was used for comparison and served as a control. Florescent microscopy image of the transfected cells that were obtained 24 hr after transfection revealed that the wild type AAV2 virus tranfected few cells in both cell types. However, the Serine 264 to Alanine mutated AAV2 virus was considerably more effective in transfecting the two cell types. Flow cytometry analysis of the transfected cells showed that the mutation of the Ser residue at position 264 increased transfection efficiency of the AAV2 virus by more than 7 fold. Together, these data demonstrate that targeting the Ser amino acid motifs within the AAV virus leads to a generation of new AAV virus with significantly greater transfection efficiency than the wild type AAV2 virus. This can have a significant impact on gene therapy approaches by reducing the number of viral particle that need to be injected into a patient to produce therapeutic level of transgene; thus, significantly reducing the side effects and improving the efficiency of gene transfer and gene therapy. Thus, in accordance with an embodiment described herein, Serine 264 to Alanine mutated AAV2 serves as a novel enhanced and safer platform for gene transfer and gene therapy of a variety of diseases and conditions including but not limited to cardiovascular disease.

In one embodiment, the present invention provides a method of improving efficiency of gene transfer and/or gene therapy to a cell by inhibiting phosphorylation of one or more serine residues of a virus capsid protein, where the inhibition of the phosphorylation of one or more serine residues results in a decrease of ubiquitination of the virus capsid protein in the cell. In another embodiment, the decrease of ubiquitination of the capsid protein results in a decrease in proteasome-mediated degradation of the capsid. In another embodiment, the inhibition of the phosphorylation of one or more serine residues is caused by mutating the serine residue. In another embodiment, one of the one or more serine residues is Serine 264. In another embodiment, the Serine 264 residue is mutated to Alanine (S 264 A). In another embodiment, the virus is AAV. In another embodiment, the virus is AAV2.

In another embodiment, the present invention provides a method of performing gene transfer and/or gene therapy by transducing a cell using an AAV2 vector, where the AAV2 vector contains one or more mutated serine residues. In another embodiment, the one or more mutated serine residues prevent ubiquitination of AAV2 and block proteasome-mediated degradation. In another embodiment, the one or more mutated serine residues allows generation of high-titer virus. In another embodiment, the mutated serine residues are at amino acid positions 264 and/or 267 of AAV2.

In various embodiments, the present invention provides biopharmaceutical compositions including a biopharmaceutically acceptable excipient along with a therapeutically effective amount of AAV2 capsids with mutated serine residues. "Biopharmaceutically acceptable excipient" means an excipient that is useful in preparing a biopharmaceutical composition that is generally safe, non-toxic, and desirable, and includes excipients that are acceptable for veterinary use as well as for human biopharmaceutical use. Such excipients may be solid, liquid, semisolid, or, in the case of an aerosol composition, gaseous.

In various embodiments, the biopharmaceutical compositions according to the invention may be formulated for delivery via any route of administration. "Route of administration" may refer to any administration pathway known in the art, including but not limited to aerosol, nasal, oral, transmucosal, transdermal or parenteral. "Parenteral" refers to a route of administration that is generally associated with injection,

5

including intraorbital, infusion, intraarterial, intracapsular, intracardiac, intradermal, intramuscular, intraperitoneal, intrapulmonary, intraspinal, intrasternal, intrathecal, intrauterine, intravenous, subarachnoid, subcapsular, subcutaneous, transmucosal, or transtracheal. Via the parenteral route, the compositions may be in the form of solutions or suspensions for infusion or for injection, or as lyophilized powders.

The biopharmaceutical compositions according to the invention can also contain any biopharmaceutically acceptable carrier. "Biopharmaceutically acceptable carrier" as used herein refers to a pharmaceutically acceptable material, composition, or vehicle that is involved in carrying or transporting a compound of interest from one tissue, organ, or portion of the body to another tissue, organ, or portion of the body. For example, the carrier may be a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, or a combination thereof. Each component of the carrier must be "biopharmaceutically acceptable" in that it must be compatible with the other ingredients of the formulation. It must also be suitable for use in contact with any tissues or organs with which it may come in contact, meaning that it must not carry a risk of toxicity, irritation, allergic response, immunogenicity, or any other complication that excessively outweighs its therapeutic benefits.

The biopharmaceutical compositions according to the invention can also be encapsulated, tableted or prepared in an emulsion or syrup for oral administration. Biopharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition. Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline, alcohols and water. Solid carriers include starch, lactose, calcium sulfate, dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin. The carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.

The biopharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulation, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension. Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.

The biopharmaceutical compositions according to the invention may be delivered in a therapeutically effective amount. The precise therapeutically effective amount is that amount of the composition that will yield the most effective results in terms of efficacy of treatment in a given subject. This amount will vary depending upon a variety of factors, including but not limited to the characteristics of the therapeutic compound (including activity, pharmacokinetics, pharmacodynamics, and bioavailability), the physiological condition of the subject (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage, and type of medication), the nature of the biopharmaceutically acceptable carrier or carriers in the formulation, and the route of administration. One skilled in the clinical and biopharmacological arts will be able to determine a therapeutically effective amount through routine experimentation, for instance, by monitoring a subject's response to administration of a compound and adjusting the dosage accordingly. For additional guidance, see *Remington: The Science and Practice of Pharmacy* (Gennaro ed. 20th edition, Williams & Wilkins PA, USA) (2000).

Typical dosages of an effective AAV2 capsid with one or more mutated serine residues can be in the ranges recom-

6

mended by the manufacturer where known therapeutic compounds are used, and also as indicated to the skilled artisan by the in vitro responses or responses in animal models. Such dosages typically can be reduced by up to about one order of magnitude in concentration or amount without losing the relevant biological activity. Thus, the actual dosage will depend upon the judgment of the physician, the condition of the patient, and the effectiveness of the therapeutic method based, for example, on the in vitro responsiveness of the relevant primary cultured cells or histocultured tissue sample, such as biopsied malignant tumors, or the responses observed in the appropriate animal models, as previously described.

One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is in no way limited to the methods and materials described. For purposes of the present invention, the following terms are defined below.

EXAMPLES

The following examples are provided to better illustrate the claimed invention and are not to be interpreted as limiting the scope of the invention. To the extent that specific materials are mentioned, it is merely for purposes of illustration and is not intended to limit the invention. One skilled in the art may develop equivalent means or reactants without the exercise of inventive capacity and without departing from the scope of the invention.

Example 1

Ubiquitination Binding Motifs

Protein ubiquitination regulates protein localization, activity and substrate specificity¹⁵. Now, protein ubiquitination is considered one of the main regulatory mechanisms in eukaryotic cells and one of the principal roles is to target the half-life of proteins by targeting them for proteasomal degradation^{15, 16}. The SCF (Skp1, Cul1 and F-box protein) complex E3 ubiquitin ligases target many proteins including Ikb α , β -catenin, and interferon- α receptor for proteolysis in diverse cellular processes, whether receptor tyrosine kinases are also targeted by SCF complex E3 ligases is not known. β -Trcp proteins serve as the substrate recognition subunits for the SCF complexes¹⁵. To date, two mammalian β -Trcp (β -transducin repeat containing protein) namely β -Trcp1 and β -Trcp2 have been identified¹⁵, although it is not clear whether they have overlapping role or each of them recognizes specific substrates. A recent study indicates that β -Trcp recognizes the doubly phosphorylated DSG motif (DpSG- Φ XpS, where Φ represents a hydrophobic and X represents any amino acid). In addition to the DSG motif, a recent study by Kanemori et al. (2005) indicates that β -Trcp binds to *Xenopus* Cdc25A via a novel non-phosphorylated binding motif, DDG Φ XD¹⁷.

Example 2

Phosphorylation of Serine for Ubiquitination

Based on the sequence homology analysis we recently found that AAV2 capsids contain a motif, ₂₆₄SGAS₂₆₇. While this mutation is not identical to the reported DSG motif, the inventors hypothesized that the amino acid sequence motif is close enough to the sequence motif recognized by the F-box proteins. This suggests that this motif in the AAV2 capsids is recognized by the ubiquitin system leading to the degradation

of the virus. The phosphorylation of capsid proteins at Serine residues is required for ubiquitination of intact AAV2 particles and that a substantial number of ubiquitinated virions are recognized and degraded by ubiquitin system leading to inefficient nuclear transport. Therefore, the inventors reasoned that substitution of Serines within the motif will allow the vector to resist ubiquitination and, thus, proteasome-mediated degradation.

Example 3

Serine 264 to Alanine Mutated AAV2

Greater Transfection Efficiency

The inventors mutated the amino acid Serine 264 into Alanine. The HeLa and HepG2 cells, two cell types that are widely used for the transfection of AAV2 virus was transfected with the mutated virus expressing green fluorescent protein (GFP) as a reporter gene. Transfection with the wild type AAV2 virus was used for comparison and served as a control. Fluorescent microscopy image of the transfected cells that were obtained 24 hr after transfection revealed that the wild type AAV2 virus transfected few cells in both cell types. However, the Serine 264 to Alanine mutated AAV2 virus was considerably more effective in transfecting the two cell types. Flow cytometry analysis of the transfected cells showed that the mutation of the Ser residue at position 264 increased transfection efficiency of the AAV2 virus by more than 7 fold. Together, these data demonstrate that targeting the Ser amino acid motifs within the AAV virus leads to a generation of new AAV virus with significantly greater transfection efficiency than the wild type AAV2 virus. This can have a significant impact on gene therapy approaches by reducing the number of viral particle that need to be injected into a patient to produce therapeutic level of transgene; thus, significantly reducing the side effects and improving the efficiency of gene transfer and gene therapy. Thus, in accordance with an embodiment described herein, Serine 264 to Alanine mutated AAV2 serves as a novel enhanced and safer platform for gene transfer and gene therapy of a variety of diseases and conditions including but not limited to cardiovascular disease.

While the description above refers to particular embodiments of the present invention, it should be readily apparent to people of ordinary skill in the art that a number of modifications may be made without departing from the spirit thereof. The presently disclosed embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

Various embodiments of the invention are described above in the Detailed Description. While these descriptions directly describe the above embodiments, it is understood that those skilled in the art may conceive modifications and/or variations to the specific embodiments shown and described herein. Any such modifications or variations that fall within the purview of this description are intended to be included therein as well. Unless specifically noted, it is the intention of the inventor that the words and phrases in the specification and claims be given the ordinary and accustomed meanings to those of ordinary skill in the applicable art(s).

The foregoing description of various embodiments of the invention known to the applicant at this time of filing the application has been presented and is intended for the purposes of illustration and description. The present description is not intended to be exhaustive nor limit the invention to the precise form disclosed and many modifications and variations are possible in the light of the above teachings. The embodiments described serve to explain the principles of the inven-

tion and its practical application and to enable others skilled in the art to utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated. Therefore, it is intended that the invention not be limited to the particular embodiments disclosed for carrying out the invention.

While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that, based upon the teachings herein, changes and modifications may be made without departing from this invention and its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as are within the true spirit and scope of this invention. Furthermore, it is to be understood that the invention is solely defined by the appended claims. It will be understood by those within the art that, in general, terms used herein, and especially in the appended claims (e.g., bodies of the appended claims) are generally intended as "open" terms (e.g., the term "including" should be interpreted as "including but not limited to," the term "having" should be interpreted as "having at least," the term "includes" should be interpreted as "includes but is not limited to," etc.). It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases "at least one" and "one or more" to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles "a" or "an" limits any particular claim containing such introduced claim recitation to inventions containing only one such recitation, even when the same claim includes the introductory phrases "one or more" or "at least one" and indefinite articles such as "a" or "an" (e.g., "a" and/or "an" should typically be interpreted to mean "at least one" or "one or more"); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should typically be interpreted to mean at least the recited number (e.g., the bare recitation of "two recitations," without other modifiers, typically means at least two recitations, or two or more recitations).

Accordingly, the invention is not limited except as by the appended claims.

REFERENCES

1. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. *Curr Top Microbiol Immunol.* 1992; 158:97-129.
2. Podsakoff G, Wong K K, Jr., Chatterjee S. Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. *J. Virol.* 1994; 68:5656-5666.
3. Flotte T R, Afione S A, Conrad C, McGrath S A, Solow R, Oka H, Zeitlin P L, Guggino W B, Carter B J. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. *Proceedings of the National Academy of Sciences of the United States of America.* 1993; 90:10613-10617.
4. Xiao X, Li J, Samulski R J. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. *J. Virol.* 1996; 70:8098-8108.
5. Snyder R O, Miao C H, Patijn G A, Spratt S K, Danos O, Nagy D, Gown A M, Winther B, Meuse L, Cohen L K,

- Thompson A R, Kay M A. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. *Nat Genet.* 1997; 16:270-276.
6. Flotte T, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, Taylor G, Walden S, Wetzel R. A Phase I Study of an Adeno-Associated Virus-CFTR Gene Vector in Adult CF Patients with Mild Lung Disease. Johns Hopkins Children's Center, Baltimore, Md. *Human Gene Therapy.* 1996; 7:1145-1159.
7. Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV2-CB-hAAT) Gene Vector to AAT-Deficient Adults. *Human Gene Therapy.* 2004; 15:93-128.
8. Kay M A, Manno C S, Ragni M V, Larson P J, Couto L B, McClelland A, Glader B, Chew A J, J Tai S, Herzog R W, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake A W, High K A. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. *Nat Genet.* 2000; 24:257-261.
9. Zabner J, Seiler M, Walters R, Kotin R M, Fulgeras W, Davidson B L, Chiorini J A. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. *J. Virol.* 2000; 74:3852-3858.
10. Thomas C E, Storm T A, Huang Z, Kay M A. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. *J. Virol.* 2004; 78:3110-3122.

11. Douar A-M, Poulard K, Stockholm D, Danos O. Intracellular Trafficking of Adeno-Associated Virus Vectors: Routing to the Late Endosomal Compartment and Proteasome Degradation. *J. Virol.* 2001; 75: 1824-1833.
12. Ding W, Zhang L N, Yeaman C, Engelhardt J F. rAAV2 Traffics through both the Late and the Recycling Endosomes in a Dose-Dependent Fashion. *Mol Ther.* 2006; 13:671-682.
13. Zhong L, Zhao W, Wu J, Li B, Zolotukhin S, Govindasamy L, Agbandje-McKenna M, Srivastava A. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. *Mol Ther.* 2007; 15:1323-1330.
14. Zhong L, Li B, Mah C S, Govindasamy L, Agbandje-McKenna M, Cooper M, Herzog R W, Zolotukhin I, Warrington K H, Jr., Weigel-Van Aken K A, Hobbs J A, Zolotukhin S, Muzyczka N, Srivastava A. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. *Proc Natl Acad Sci USA.* 2008; 105:7827-7832.
15. Cardozo T, Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. *Nat Rev Mol Cell Biol.* 2004; 5:739-751.
16. Vaux D L, Silke J. IAPs, RINGS and ubiquitylation. *Nat Rev Mol Cell Biol.* 2005; 6:287-297.
17. Kanemori Y, Uto K, Sagata N. Beta-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases. *Proc Natl Acad Sci USA.* 2005; 102:6279-6284.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 4

<210> SEQ ID NO 1

<211> LENGTH: 735

<212> TYPE: PRT

<213> ORGANISM: adeno-associated virus

<400> SEQUENCE: 1

```

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Thr Leu Ser
 1             5             10            15

Glu Gly Ile Arg Gln Trp Trp Lys Leu Lys Pro Gly Pro Pro Pro Pro
          20             25            30

Lys Pro Ala Glu Arg His Lys Asp Asp Ser Arg Gly Leu Val Leu Pro
          35             40            45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
          50             55            60

Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
          65             70            75            80

Arg Gln Leu Asp Ser Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
          85             90            95

Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
          100            105           110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
          115            120           125

Leu Gly Leu Val Glu Glu Pro Val Lys Thr Ala Pro Gly Lys Lys Arg
          130            135           140

Pro Val Glu His Ser Pro Val Glu Pro Asp Ser Ser Ser Gly Thr Gly
          145            150           155           160

Lys Ala Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln Thr
          165            170           175

```

Gly 180	Asp 180	Ala 180	Val 180	Ser 180	Pro 180	Asp 180	Pro 185	Gln 185	Pro 185	Leu 185	Gly 190	Gln 190	Pro 190	Pro 190
Ala 195	Pro 195	Ser 195	Gly 195	Leu 195	Gly 200	Thr 200	Asn 200	Thr 200	Met 200	Ala 205	Thr 205	Gly 205	Ser 205	Gly 205
Ala 210	Pro 210	Met 210	Ala 210	Asp 210	Asn 215	Glu 215	Gly 215	Ala 215	Asp 220	Gly 220	Val 220	Gly 220	Asn 220	Ser 220
Ser 225	Gly 225	Asn 225	Trp 225	His 230	Cys 230	Asp 230	Ser 230	Thr 230	Trp 235	Met 235	Gly 235	Asp 235	Arg 235	Ile 240
Thr 245	Thr 245	Ser 245	Thr 245	Arg 245	Thr 245	Trp 245	Ala 250	Leu 250	Pro 250	Thr 250	Tyr 250	Asn 255	Asn 255	His 255
Tyr 260	Lys 260	Gln 260	Ile 260	Ser 260	Ser 260	Gln 260	Ser 265	Gly 265	Ala 265	Ser 265	Asn 265	Asp 270	Asn 270	His 270
Phe 275	Gly 275	Tyr 275	Ser 275	Thr 275	Pro 275	Trp 275	Gly 280	Tyr 280	Phe 280	Asp 280	Phe 285	Asn 285	Arg 285	Phe 285
Cys 290	His 290	Phe 290	Ser 290	Pro 290	Arg 290	Asp 295	Trp 295	Gln 295	Arg 295	Leu 300	Ile 300	Asn 300	Asn 300	Asn 300
Gly 305	Phe 305	Arg 305	Pro 305	Lys 310	Arg 310	Leu 310	Asn 310	Phe 315	Lys 315	Leu 315	Phe 315	Asn 320	Ile 320	Gln 320
Lys 325	Glu 325	Val 325	Thr 325	Gln 325	Asn 325	Asp 325	Gly 330	Thr 330	Thr 330	Thr 330	Ile 335	Ala 335	Asn 335	Asn 335
Thr 340	Ser 340	Thr 340	Val 340	Gln 340	Val 340	Phe 340	Thr 345	Asp 345	Ser 345	Glu 345	Tyr 350	Gln 350	Leu 350	Pro 350
Val 355	Leu 355	Gly 355	Ser 355	Ala 355	His 355	Gln 360	Gly 360	Cys 360	Leu 360	Pro 360	Pro 365	Phe 365	Pro 365	Ala 365
Val 370	Phe 370	Met 370	Val 370	Pro 370	Gln 370	Tyr 375	Gly 375	Tyr 375	Leu 375	Thr 375	Leu 380	Asn 380	Asn 380	Gly 380
Gln 385	Ala 385	Val 385	Gly 385	Arg 385	Ser 390	Ser 390	Phe 390	Tyr 390	Cys 395	Leu 395	Glu 395	Tyr 395	Phe 395	Pro 395
Gln 405	Met 405	Leu 405	Arg 405	Thr 405	Gly 405	Asn 410	Asn 410	Phe 410	Thr 410	Phe 410	Ser 415	Tyr 415	Thr 415	Phe 415
Asp 420	Val 420	Pro 420	Phe 420	His 420	Ser 420	Ser 425	Tyr 425	Ala 425	His 425	Ser 430	Gln 430	Ser 430	Leu 430	Asp 430
Leu 435	Met 435	Asn 435	Pro 435	Leu 435	Ile 435	Asp 440	Gln 440	Tyr 440	Leu 440	Tyr 440	Tyr 445	Leu 445	Ser 445	Arg 445
Asn 450	Thr 450	Pro 450	Ser 450	Gly 450	Thr 450	Thr 455	Thr 455	Gln 455	Ser 455	Arg 460	Leu 460	Gln 460	Phe 460	Ser 460
Ala 465	Gly 465	Ala 465	Ser 465	Asp 465	Ile 470	Arg 470	Asp 470	Gln 470	Ser 470	Arg 475	Asn 475	Trp 475	Leu 475	Pro 475
Pro 485	Cys 485	Tyr 485	Arg 485	Gln 485	Gln 485	Arg 485	Val 485	Ser 485	Lys 490	Thr 490	Ser 490	Ala 490	Asp 490	Asn 490
Asn 500	Ser 500	Glu 500	Tyr 500	Ser 500	Trp 500	Thr 500	Gly 500	Ala 505	Thr 505	Lys 505	Tyr 505	His 510	Leu 510	Asn 510
Arg 515	Asp 515	Ser 515	Leu 515	Val 515	Asn 515	Pro 515	Gly 520	Pro 520	Ala 520	Met 520	Ala 520	Ser 525	His 525	Lys 525
Asp 530	Glu 530	Glu 530	Lys 530	Phe 530	Phe 530	Pro 535	Gln 535	Ser 535	Gly 535	Val 540	Leu 540	Ile 540	Phe 540	Gly 540
Gln 545	Gly 545	Ser 545	Glu 545	Lys 545	Thr 545	Asn 545	Val 545	Asp 545	Ile 545	Glu 550	Lys 550	Val 550	Met 550	Ile 550
Asp 565	Glu 565	Glu 565	Glu 565	Ile 565	Arg 565	Thr 565	Thr 565	Asn 565	Pro 570	Val 570	Ala 570	Thr 570	Glu 570	Gln 570
Gly 580	Ser 580	Val 580	Ser 580	Thr 580	Asn 580	Leu 580	Gln 580	Arg 580	Gly 585	Asn 585	Arg 585	Gln 585	Ala 585	

-continued

Ala	Asp	Val	Asn	Thr	Gln	Gly	Val	Leu	Pro	Gly	Met	Val	Trp	Gln	Asp
	595						600					605			
Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	Pro	His	Thr
	610					615					620				
Asp	Gly	His	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	Gly	Leu	Lys
	625				630					635					640
His	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	Pro	Ala	Asn
				645					650					655	
Pro	Ser	Thr	Thr	Phe	Ser	Ala	Ala	Lys	Phe	Ala	Ser	Phe	Ile	Thr	Gln
			660					665					670		
Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu	Leu	Gln	Lys
		675					680					685			
Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Ile	Gln	Tyr	Thr	Ser	Asn	Tyr
	690					695					700				
Asn	Lys	Ser	Val	Asn	Val	Asp	Phe	Thr	Val	Asp	Thr	Asn	Gly	Val	Tyr
	705				710					715					720
Ser	Glu	Pro	Arg	Pro	Ile	Gly	Thr	Arg	Tyr	Leu	Thr	Arg	Asn	Leu	
			725						730					735	

<210> SEQ ID NO 2

<211> LENGTH: 735

<212> TYPE: PRT

<213> ORGANISM: adeno-associated virus

<400> SEQUENCE: 2

Met	Ala	Ala	Asp	Gly	Tyr	Leu	Pro	Asp	Trp	Leu	Glu	Asp	Thr	Leu	Ser
1			5					10						15	
Glu	Gly	Ile	Arg	Gln	Trp	Trp	Lys	Leu	Lys	Pro	Gly	Pro	Pro	Pro	Pro
		20					25					30			
Lys	Pro	Ala	Glu	Arg	His	Lys	Asp	Asp	Ser	Arg	Gly	Leu	Val	Leu	Pro
		35				40						45			
Gly	Tyr	Lys	Tyr	Leu	Gly	Pro	Phe	Asn	Gly	Leu	Asp	Lys	Gly	Glu	Pro
	50				55						60				
Val	Asn	Glu	Ala	Asp	Ala	Ala	Ala	Leu	Glu	His	Asp	Lys	Ala	Tyr	Asp
	65			70					75					80	
Arg	Gln	Leu	Asp	Ser	Gly	Asp	Asn	Pro	Tyr	Leu	Lys	Tyr	Asn	His	Ala
			85					90						95	
Asp	Ala	Glu	Phe	Gln	Glu	Arg	Leu	Lys	Glu	Asp	Thr	Ser	Phe	Gly	Gly
		100					105						110		
Asn	Leu	Gly	Arg	Ala	Val	Phe	Gln	Ala	Lys	Lys	Arg	Val	Leu	Glu	Pro
	115					120						125			
Leu	Gly	Leu	Val	Glu	Glu	Pro	Val	Lys	Thr	Ala	Pro	Gly	Lys	Lys	Arg
	130				135						140				
Pro	Val	Glu	His	Ser	Pro	Val	Glu	Pro	Asp	Ser	Ser	Ser	Gly	Thr	Gly
	145			150					155					160	
Lys	Ala	Gly	Gln	Gln	Pro	Ala	Arg	Lys	Arg	Leu	Asn	Phe	Gly	Gln	Thr
			165					170						175	
Gly	Asp	Ala	Asp	Ser	Val	Pro	Asp	Pro	Gln	Pro	Leu	Gly	Gln	Pro	Pro
		180					185						190		
Ala	Ala	Pro	Ser	Gly	Leu	Gly	Thr	Asn	Thr	Met	Ala	Thr	Gly	Ser	Gly
		195					200					205			
Ala	Pro	Met	Ala	Asp	Asn	Asn	Glu	Gly	Ala	Asp	Gly	Val	Gly	Asn	Ser
	210				215						220				
Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Thr	Trp	Met	Gly	Asp	Arg	Val	Ile
	225				230					235					240

Thr	Thr	Ser	Thr	Arg	Thr	Trp	Ala	Leu	Pro	Thr	Tyr	Asn	Asn	His	Leu	
				245					250					255		
Tyr	Lys	Gln	Ile	Ser	Ser	Gln	Ala	Gly	Ala	Ser	Asn	Asp	Asn	His	Tyr	
				260					265					270		
Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	Arg	Phe	His	
				275					280					285		
Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	Asn	Trp	
				290					295					300		
Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	Phe	Lys	Leu	Phe	Asn	Ile	Gln	Val	
				305					310					315		
Lys	Glu	Val	Thr	Gln	Asn	Asp	Gly	Thr	Thr	Thr	Ile	Ala	Asn	Asn	Leu	
				325					330					335		
Thr	Ser	Thr	Val	Gln	Val	Phe	Thr	Asp	Ser	Glu	Tyr	Gln	Leu	Pro	Tyr	
				340					345					350		
Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	Pro	Ala	Asp	
				355					360					365		
Val	Phe	Met	Val	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asn	Gly	Ser	
				370					375					380		
Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	Pro	Ser	
				385					390					395		
Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Thr	Phe	Ser	Tyr	Thr	Phe	Glu	
				405					410					415		
Asp	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	Asp	Arg	
				420					425					430		
Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Ser	Arg	Thr	
				435					440					445		
Asn	Thr	Pro	Ser	Gly	Thr	Thr	Thr	Gln	Ser	Arg	Leu	Gln	Phe	Ser	Gln	
				450					455					460		
Ala	Gly	Ala	Ser	Asp	Ile	Arg	Asp	Gln	Ser	Arg	Asn	Trp	Leu	Pro	Gly	
				465					470					475		
Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Lys	Thr	Ser	Ala	Asp	Asn	Asn	
				485					490					495		
Asn	Ser	Glu	Tyr	Ser	Trp	Thr	Gly	Ala	Thr	Lys	Tyr	His	Leu	Asn	Gly	
				500					505					510		
Arg	Asp	Ser	Leu	Val	Asn	Pro	Gly	Pro	Ala	Met	Ala	Ser	His	Lys	Asp	
				515					520					525		
Asp	Glu	Glu	Lys	Phe	Phe	Pro	Gln	Ser	Gly	Val	Leu	Ile	Phe	Gly	Lys	
				530					535					540		
Gln	Gly	Ser	Glu	Lys	Thr	Asn	Val	Asp	Ile	Glu	Lys	Val	Met	Ile	Thr	
				545					550					555		
Asp	Glu	Glu	Glu	Ile	Arg	Thr	Thr	Asn	Pro	Val	Ala	Thr	Glu	Gln	Tyr	
				565					570					575		
Gly	Ser	Val	Ser	Thr	Asn	Leu	Gln	Arg	Gly	Asn	Arg	Gln	Ala	Ala	Thr	
				580					585					590		
Ala	Asp	Val	Asn	Thr	Gln	Gly	Val	Leu	Pro	Gly	Met	Val	Trp	Gln	Asp	
				595					600					605		
Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	Pro	His	Thr	
				610					615					620		
Asp	Gly	His	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	Gly	Leu	Lys	
				625					630					635		
His	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	Pro			

-continued

Pro	Ser	Thr	Thr	Phe	Ser	Ala	Ala	Lys	Phe	Ala	Ser	Phe	Ile	Thr	Gln
			660					665					670		
Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu	Leu	Gln	Lys
		675					680					685			
Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Ile	Gln	Tyr	Thr	Ser	Asn	Tyr
	690					695					700				
Asn	Lys	Ser	Val	Asn	Val	Asp	Phe	Thr	Val	Asp	Thr	Asn	Gly	Val	Tyr
	705				710					715					720
Ser	Glu	Pro	Arg	Pro	Ile	Gly	Thr	Arg	Tyr	Leu	Thr	Arg	Asn	Leu	
				725					730					735	

<210> SEQ ID NO 3
 <211> LENGTH: 735
 <212> TYPE: PRT
 <213> ORGANISM: adeno-associated virus

<400> SEQUENCE: 3

Met	Ala	Ala	Asp	Gly	Tyr	Leu	Pro	Asp	Trp	Leu	Glu	Asp	Thr	Leu	Ser
1			5					10					15		
Glu	Gly	Ile	Arg	Gln	Trp	Trp	Lys	Leu	Lys	Pro	Gly	Pro	Pro	Pro	Pro
		20					25					30			
Lys	Pro	Ala	Glu	Arg	His	Lys	Asp	Asp	Ser	Arg	Gly	Leu	Val	Leu	Pro
		35					40					45			
Gly	Tyr	Lys	Tyr	Leu	Gly	Pro	Phe	Asn	Gly	Leu	Asp	Lys	Gly	Glu	Pro
	50				55						60				
Val	Asn	Glu	Ala	Asp	Ala	Ala	Ala	Leu	Glu	His	Asp	Lys	Ala	Tyr	Asp
	65			70					75						80
Arg	Gln	Leu	Asp	Ser	Gly	Asp	Asn	Pro	Tyr	Leu	Lys	Tyr	Asn	His	Ala
			85					90						95	
Asp	Ala	Glu	Phe	Gln	Glu	Arg	Leu	Lys	Glu	Asp	Thr	Ser	Phe	Gly	Gly
		100					105						110		
Asn	Leu	Gly	Arg	Ala	Val	Phe	Gln	Ala	Lys	Lys	Arg	Val	Leu	Glu	Pro
	115						120					125			
Leu	Gly	Leu	Val	Glu	Glu	Pro	Val	Lys	Thr	Ala	Pro	Gly	Lys	Lys	Arg
	130					135					140				
Pro	Val	Glu	His	Ser	Pro	Val	Glu	Pro	Asp	Ser	Ser	Ser	Gly	Thr	Gly
	145				150					155					160
Lys	Ala	Gly	Gln	Gln	Pro	Ala	Arg	Lys	Arg	Leu	Asn	Phe	Gly	Gln	Thr
			165					170						175	
Gly	Asp	Ala	Asp	Ser	Val	Pro	Asp	Pro	Gln	Pro	Leu	Gly	Gln	Pro	Pro
		180						185					190		
Ala	Ala	Pro	Ser	Gly	Leu	Gly	Thr	Asn	Thr	Met	Ala	Thr	Gly	Ser	Gly
		195					200					205			
Ala	Pro	Met	Ala	Asp	Asn	Asn	Glu	Gly	Ala	Asp	Gly	Val	Gly	Asn	Ser
	210				215						220				
Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Thr	Trp	Met	Gly	Asp	Arg	Val	Ile
	225				230					235					240
Thr	Thr	Ser	Thr	Arg	Thr	Trp	Ala	Leu	Pro	Thr	Tyr	Asn	Asn	His	Leu
			245						250					255	
Tyr	Lys	Gln	Ile	Ser	Ser	Gln	Ala	Gly	Ala	Ala	Asn	Asp	Asn	His	Tyr
		260						265					270		
Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	Arg	Phe	His
		275					280					285			
Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	Asn	Trp
	290					295					300				

-continued

Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	Phe	Lys	Leu	Phe	Asn	Ile	Gln	Val	
305					310					315					320	
Lys	Glu	Val	Thr	Gln	Asn	Asp	Gly	Thr	Thr	Thr	Ile	Ala	Asn	Asn	Leu	
				325				330						335		
Thr	Ser	Thr	Val	Gln	Val	Phe	Thr	Asp	Ser	Glu	Tyr	Gln	Leu	Pro	Tyr	
			340					345					350			
Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	Pro	Ala	Asp	
	355					360						365				
Val	Phe	Met	Val	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asn	Gly	Ser	
	370					375					380					
Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	Pro	Ser	
385					390					395					400	
Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Thr	Phe	Ser	Tyr	Thr	Phe	Glu	
			405					410						415		
Asp	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	Asp	Arg	
			420					425					430			
Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Ser	Arg	Thr	
	435					440						445				
Asn	Thr	Pro	Ser	Gly	Thr	Thr	Thr	Gln	Ser	Arg	Leu	Gln	Phe	Ser	Gln	
	450					455					460					
Ala	Gly	Ala	Ser	Asp	Ile	Arg	Asp	Gln	Ser	Arg	Asn	Trp	Leu	Pro	Gly	
465					470					475					480	
Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Lys	Thr	Ser	Ala	Asp	Asn	Asn	
			485					490						495		
Asn	Ser	Glu	Tyr	Ser	Trp	Thr	Gly	Ala	Thr	Lys	Tyr	His	Leu	Asn	Gly	
		500						505					510			
Arg	Asp	Ser	Leu	Val	Asn	Pro	Gly	Pro	Ala	Met	Ala	Ser	His	Lys	Asp	
	515					520					525					
Asp	Glu	Glu	Lys	Phe	Phe	Pro	Gln	Ser	Gly	Val	Leu	Ile	Phe	Gly	Lys	
	530					535				540						
Gln	Gly	Ser	Glu	Lys	Thr	Asn	Val	Asp	Ile	Glu	Lys	Val	Met	Ile	Thr	
545				550					555					560		
Asp	Glu	Glu	Glu	Ile	Arg	Thr	Thr	Asn	Pro	Val	Ala	Thr	Glu	Gln	Tyr	
			565					570					575			
Gly	Ser	Val	Ser	Thr	Asn	Leu	Gln	Arg	Gly	Asn	Arg	Gln	Ala	Ala	Thr	
		580						585					590			
Ala	Asp	Val	Asn	Thr	Gln	Gly	Val	Leu	Pro	Gly	Met	Val	Trp	Gln	Asp	
	595				600						605					
Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	Pro	His	Thr	
	610				615					620						
Asp	Gly	His	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	Gly	Leu	Lys	
625				630					635					640		
His	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	Pro	Ala	Asn	
			645					650					655			
Pro	Ser	Thr	Thr	Phe	Ser	Ala	Ala	Lys	Phe	Ala	Ser	Phe	Ile	Thr	Gln	
		660						665					670			
Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu	Leu	Gln	Lys	
	675					680						685				
Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Ile	Gln	Tyr	Thr	Ser	Asn	Tyr	
	690				695						700					
Asn	Lys	Ser	Val	Asn	Val	Asp	Phe	Thr	Val	Asp	Thr	Asn	Gly	Val	Tyr	
705				710						715					720	

-continued

Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
 725 730 735

<210> SEQ ID NO 4
 <211> LENGTH: 4
 <212> TYPE: PRT
 <213> ORGANISM: adeno-associated virus

<400> SEQUENCE: 4

Ser Gly Ala Ser
 1

The invention claimed is:

1. A vector, comprising:
 an isolated adeno-associated virus (AAV) capsid comprising SEQ. ID. NO.: 2 or SEQ ID NO: 3 that resist ubiquitination.
2. The vector of claim 1, wherein the isolated AAV capsid comprises SEQ. ID. NO.: 2.
3. The vector of claim 1, wherein the isolated AAV capsid comprises SEQ. ID. NO.: 3.
4. A method of increasing transfection efficiency in an adeno-associated virus (AAV) capsid, comprising:
 providing a wild-type AAV2 capsid comprising a Serine Glycine Alanine Serine (SGAS) (SEQ ID NO:4) motif; and
 mutating one or more residues in the SGAS (SEQ ID NO:4) motif on the wild-type AAV2 capsid to resist ubiquitination to result in a AAV2 capsid comprising SEQ. ID. NO.: 2 or SEQ. ID. NO.: 3.

- 15 5. The method of claim 4, wherein mutating the one or more residues in the SGAS (SEQ ID NO:4) motif on the AAV capsid results in the AAV capsid comprising SEQ. ID. NO.: 2.
- 20 6. A method of transfecting a cell, comprising:
 providing an isolated adeno-associated virus (AAV) capsid comprising SEQ ID NO: 2 or SEQ ID NO:3 that resist ubiquitination; and
 transfecting the cell with the AAV capsid.
- 25 7. The method of claim 6, wherein the cell is a HeLa and/or HepG2 cell.
8. The method of claim 6, wherein the cell is transfected directly.
9. The method of claim 6, wherein the isolated AAV capsid comprises SEQ. ID. NO.: 2.
10. The method of claim 6, wherein the isolated AAV capsid comprises SEQ. ID. NO.: 3.
- 30 11. The method of claim 4, wherein mutating the one or more residues in the SGAS (SEQ ID NO:4) motif on the AAV capsid results in the AAV capsid comprising SEQ. ID. NO.: 3.

* * * * *